Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Two "forever chemicals" found in everyday products are linked to dramatically higher rates of an aggressive breast cancer subtype. An NIH study found women with the highest blood levels of PFOA and PFOS had up to 93% higher rates of estrogen receptor-negative breast cancer — a particularly hard-to-treat form of the disease. Researchers say exposure may be modifiable, opening new doors for prevention.
Two widely encountered "forever chemicals" — PFOA and PFOS — are linked to significantly higher rates of estrogen receptor-negative (ER-negative) breast cancer, according to a new NIH study published in the Journal of Clinical Oncology. ER-negative breast cancer is more aggressive and has fewer known risk factors than hormone receptor-positive forms, making these findings especially significant for women's health.
Researchers analyzed blood samples collected before cancer diagnoses from participants in the Sister Study, a major NIH cohort of over 50,000 women. They measured 17 different PFAS chemicals and compared exposure levels to subsequent breast cancer outcomes, finding stark differences for two specific compounds. Because the strongest associations appeared in ER-negative tumors, researchers believe PFAS may act through non-hormonal mechanisms — such as epigenetic changes or immune system disruption — rather than by mimicking estrogen.
By the Numbers:
Why it matters: PFAS chemicals are found in countless consumer products and persist in both the environment and the human body for years. While PFOA and PFOS have largely been phased out, measurable levels remain in most people. Researchers stress that exposure is potentially modifiable — and that newer replacement PFAS chemicals urgently need similar scrutiny.
